SIGLEC15 and glioma: In addition, the ROC results showed that the AUC of Siglec15 expression in glioma patients was 0.728 for 1-year survival, 0.694 for 2-year survival and 0.686 for 3-year survival in the TCGA database and 0.623 for 1-year survival, 0.627 for 2-year survival and 0.632 for 3-year survival in the CGGA database.